Trial · NCT04898712
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma -2
NCT04898712, Phase 2, Unknown, Unity Health Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma -2. Trials, record NCT04898712. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04898712
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma -2
- NCT number
- NCT04898712
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Unity Health Toronto
- Conditions
- Chronic Subdural Hematoma
- Interventions
- Tranexamic Acid 500 MG, Placebo
- First posted
- 2021-05-24
- Last updated
- 2021-05-24
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Chronic subdural hematoma volume change | At 4-8 weeks | Change in hematoma volume in mL according to CT-scan-based volume measurements comparing hematoma on CT scan performed at 4-8 weeks to hematoma on immediate post-operative CT scan. |
| Secondary | Chronic subdural hematoma volume change | At 12 weeks | Change in hematoma volume in mL according to CT-scan-based volume measurements comparing hematoma on CT scan performed at 4-8 weeks to hematoma on immediate post-operative CT scan. |
| Secondary | Rate of adverse events (AEs) | At 4, 8, and 12 weeks | Adverse events investigated include: * suspected stroke * myocardial infarction * deep vein thrombosis * thromboembolic events * decline in renal function * new-onset neurological deterioration Serious adverse events include: * evidence of stroke * myocardial infarction * deep vein thrombosis * thromboembolic events * convulsions * severe allergic reactions * evidence of retinal degeneration * necessity of hospital admission * mortality |
| Secondary | 36-Item Short Form Survey (SF-36) | At 4, 8, 12 weeks | Questionnaire assessing patient quality of life outcome profile |
| Secondary | National Institutes of Health Stroke Scale (NIHSS) | At 4, 8, and 12 weeks | Change in National Institutes of Health Stroke Scale (NIHSS) score (neurological outcome) at 4-8 weeks and 8-12 weeks, compared to the baseline visit score Minimum scale score: 0; Maximum scale score: 42. Higher score means worse neurological impairment. |
| Secondary | Modified Rankin Scale (mRS) | At 4, 8, and 12 weeks | Change in Modified Rankin Scale (mRS) score (neurological outcome) at 4-8 weeks and 8-12 weeks, compared to the baseline visit score Minimum scale score: 0 (no symptoms); Maximum scale score: 6 (death). Higher score means worse neurological outcome. |
| Secondary | Markwalder's grading scale (MGS) | At 4, 8, and 12 weeks | Change in Markwalder's grading scale (MGS) score (neurological outcome) at 4-8 weeks and 8-12 weeks, compared to the baseline visit score Minimum scale score: 0 (normal); Maximum scale score: 4. Higher score means worse neurological outcome. |
| Secondary | Rate of re-operation | At 4, 8, and 12 weeks | Rate of re-operation during study course due to hematoma enlargement or other significant cause |
| Secondary | Time to reoperation | At 4, 8, and 12 weeks | Time to reoperation during study course due to hematoma enlargement or other significant cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04898712
GET https://conductscience.org/api/trials/v1/NCT04898712/registered